Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Do State Laws Protecting Older Workers from Discrimination Reduce Age Discrimination in Hiring? Evidence from a Field Experiment.

Neumark D, Burn I, Button P, Chehras N.

J Law Econ. 2019 May;62(2):373-402. doi: 10.1086/704008.

PMID:
32051647
2.

Reasons for b/tsDMARD cessation and persistence of second line treatment in a large real world rheumatoid arthritis dataset.

Youssef P, Marcal B, Button P, Truman M, Bird P, Dip G, Griffiths H, Roberts L, Tymms K, Littlejohn G.

J Rheumatol. 2019 Dec 1. pii: jrheum.190535. doi: 10.3899/jrheum.190535. [Epub ahead of print]

PMID:
31787605
3.

Do Tax Incentives Affect Business Location and Economic Development? Evidence from State Film Incentives.

Button P.

Reg Sci Urban Econ. 2019 Jul;77:315-339. doi: 10.1016/j.regsciurbeco.2019.06.002. Epub 2019 Jun 20.

PMID:
31359896
4.

How Valuable are National Parks? Evidence from a Proposed National Park Expansion in Alaska.

Johnson L, Spanbauer M, Button P.

J Park Recreat Admi. 2019;37(2). doi: 10.18666/JPRA-2019-8968.

5.

Tocilizumab Patterns of Use, Effectiveness, and Safety in Patients with Rheumatoid Arthritis: Final Results from a Set of Multi-National Non-Interventional Studies.

Haraoui B, Casado G, Czirják L, Taylor A, Dong L, Button P, Luder Y, Caporali R.

Rheumatol Ther. 2019 Jun;6(2):231-243. doi: 10.1007/s40744-019-0150-x. Epub 2019 Mar 11.

6.

Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.

Wu YL, Lee V, Liam CK, Lu S, Park K, Srimuninnimit V, Wang J, Zhou C, Appius A, Button P, Hooper G, Palma JF, Schulze K, Scudder S, Shames DS, Yin AY, Zhang G, Mok T; ENSURE FASTACT-2 and ASPIRATION Investigators.

Lung Cancer. 2018 Dec;126:1-8. doi: 10.1016/j.lungcan.2018.10.004. Epub 2018 Oct 9.

PMID:
30527172
7.

Effectiveness of biologics in Australian patients with rheumatoid arthritis: a large observational study: REAL.

Nicholls D, Barrett R, Button P, Truman M, Bird P, Roberts L, Tymms K, Littlejohn G, Griffiths H.

Intern Med J. 2018 Oct;48(10):1185-1192. doi: 10.1111/imj.14028.

PMID:
29968400
8.

A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population.

Jones G, Hall S, Bird P, Littlejohn G, Tymms K, Youssef P, Chung E, Barrett R, Button P.

Int J Rheum Dis. 2018 Aug;21(8):1581-1590. doi: 10.1111/1756-185X.13243. Epub 2017 Dec 5.

PMID:
29205926
9.

A transition from using multi-step procedures to a fully integrated system for performing extracorporeal photopheresis: A comparison of costs and efficiencies.

Azar N, Leblond V, Ouzegdouh M, Button P.

J Clin Apher. 2017 Dec;32(6):474-478. doi: 10.1002/jca.21542. Epub 2017 Apr 17.

10.

Does Protecting Older Workers From Discrimination Make It Harder to Get Hired? Evidence From Disability Discrimination Laws.

Neumark D, Song J, Button P.

Res Aging. 2017 Jan;39(1):29-63. doi: 10.1177/0164027516656142.

PMID:
28181873
11.

Improving the service for patients receiving extracorporeal photopheresis using Lean principles.

Rushton C, Robertson L, Taylor T, Taylor P, Button P, Alfred A.

Br J Nurs. 2016 Sep 8;25(16):917-21. doi: 10.12968/bjon.2016.25.16.917.

PMID:
27615528
12.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T.

JAMA Oncol. 2016 Mar;2(3):305-12. doi: 10.1001/jamaoncol.2015.4921.

PMID:
26720423
13.

Liver stiffness and the prediction of clinically significant portal hypertension and portal hypertensive complications.

Kitson MT, Roberts SK, Colman JC, Paul E, Button P, Kemp W.

Scand J Gastroenterol. 2015 Apr;50(4):462-9. doi: 10.3109/00365521.2014.964758. Epub 2015 Jan 26.

PMID:
25623641
14.

Interleukin-28B rs12979860 C allele: Protective against advanced fibrosis in chronic hepatitis C genotype 1 infection.

Kitson MT, George J, Dore GJ, Leung R, Button P, McCaughan GW, Grawford DH, Siebert W, Weltman MD, Cheng WS, Roberts SK.

J Gastroenterol Hepatol. 2014;29(7):1458-62.

PMID:
25587616
15.

Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.

Michael M, White SC, Abdi E, Nott L, Clingan P, Zimet A, Button P, Gregory D, Solomon B, Dobrovic A, Do H, Clarke S.

Asia Pac J Clin Oncol. 2015 Mar;11(1):4-14. doi: 10.1111/ajco.12178. Epub 2014 Feb 27.

PMID:
24575793
16.

Reply to: "Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection".

Kitson MT, Button P, Roberts SK; CHARIOT Publication Steering Committee.

J Hepatol. 2013 Jul;59(1):194-5. doi: 10.1016/j.jhep.2013.03.001. Epub 2013 Mar 14. No abstract available.

17.

Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection.

Kitson MT, Dore GJ, George J, Button P, McCaughan GW, Crawford DH, Sievert W, Weltman MD, Cheng WS, Roberts SK.

J Hepatol. 2013 Mar;58(3):467-72. doi: 10.1016/j.jhep.2012.11.017. Epub 2012 Nov 23.

PMID:
23183524
18.

Collaboration strategies for CDS success.

Button P.

Health Manag Technol. 2012 Jul;33(7):12-3. No abstract available.

PMID:
22908438
19.

Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program.

Bilous M, Morey AL, Armes JE, Bell R, Button PH, Cummings MC, Fox SB, Francis GD, Waite B, McCue G, Raymond WA, Robbins PD, Farshid G.

Breast Cancer Res Treat. 2012 Jul;134(2):617-24. doi: 10.1007/s10549-012-2093-6. Epub 2012 Jun 8.

20.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators.

Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.

PMID:
22226517
21.

Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.

Wardley AM, Pivot X, Morales-Vasquez F, Zetina LM, de Fátima Dias Gaui M, Reyes DO, Jassem J, Barton C, Button P, Hersberger V, Torres AA.

J Clin Oncol. 2010 Feb 20;28(6):976-83. doi: 10.1200/JCO.2008.21.6531. Epub 2009 Dec 28.

PMID:
20038734
22.

Evaluation of an interprofessional collaboration workshop for post-graduate residents, nursing and allied health professionals.

Curran VR, Heath O, Kearney A, Button P.

J Interprof Care. 2010 May;24(3):315-8. doi: 10.3109/13561820903163827. No abstract available.

PMID:
19995269
23.

A longitudinal study of the effect of an interprofessional education curriculum on student satisfaction and attitudes towards interprofessional teamwork and education.

Curran VR, Sharpe D, Flynn K, Button P.

J Interprof Care. 2010 Jan;24(1):41-52. doi: 10.3109/13561820903011927.

PMID:
19705318
24.

Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B.

Piratvisuth T, Lau G, Chao YC, Jin R, Chutaputti A, Zhang QB, Tanwandee T, Button P, Popescu M.

Hepatol Int. 2008 Mar;2(1):102-10. doi: 10.1007/s12072-007-9022-5. Epub 2008 Feb 5.

25.

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M.

Hepatology. 2008 Feb;47(2):428-34. doi: 10.1002/hep.22065.

PMID:
18220290
26.

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.

N Engl J Med. 2004 Sep 16;351(12):1206-17.

27.

Modeling nursing interventions in the act class of HL7 RIM Version 3.

Danko A, Kennedy R, Haskell R, Androwich IM, Button P, Correia CM, Grobe SJ, Harris MR, Matney S, Russler D.

J Biomed Inform. 2003 Aug-Oct;36(4-5):294-303.

28.

The nursing terminology summit: collaboration for progress.

Ozbolt J, Androwich I, Bakken S, Button P, Hardiker N, Mead C, Warren J, Zingo C.

Stud Health Technol Inform. 2001;84(Pt 1):236-40.

PMID:
11604740
29.

Challenges in the development and testing of a reference terminology model for nursing interventions.

Button PS, Androwich I, Mead CN, Zingo C, Konicek D, Campbell KE.

Stud Health Technol Inform. 2001;84(Pt 1):176-80.

PMID:
11604728
30.

Automating clinical documentation in dentistry: case study of a clinical integration model.

Button PS, Doyle K, Karitis JW, Selhorst C.

J Healthc Inf Manag. 1999 Fall;13(3):31-40. No abstract available.

PMID:
10787599
31.

Challenges and issues related to implementation of nursing vocabularies in computer-based systems.

Button P, Androwich I, Hibben L, Kern V, Madden G, Marek K, Westra B, Zingo C, Mead CN.

J Am Med Inform Assoc. 1998 Jul-Aug;5(4):332-4.

32.
33.

Nursing Interventions Classification implementation issues in five test sites.

Daly JM, Button P, Prophet CM, Clarke M, Androwich I.

Comput Nurs. 1997 Jan-Feb;15(1):23-9.

PMID:
9014390
34.

An orthopaedic theatre timings survey.

Williams N, Button P, Butler PJ.

Ann R Coll Surg Engl. 1994 Sep;76(5):355-6. No abstract available.

Supplemental Content

Loading ...
Support Center